Trial Profile
Phase I, Multicenter, Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors PharmaMar
- 29 Apr 2021 Results (N=244), Pharmacokinetic-pharmacodynamic analyses of pooled data from phase I studies A-0015 and A-005, and phase II studies B001, B-002, and B-0038 published in the Journal of Clinical Pharmacology
- 09 Aug 2018 Results of pooled data from six phase I and three phase II trials with lurbinectedin, were published in the Clinical Pharmacokinetics.
- 13 Jun 2011 Actual end date changed from 24 Nov 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.